Skip to content

EPS (Basic) at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$2.17-52.5%
Merck & Co. logo
Merck & Co.MRK
-$1.72-186%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$0.62-313%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-$1.11-35.4%
CG Oncology logo
CG OncologyCGON
-$0.71-57.8%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
-$0.22+62.1%

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s EPS (basic)?
Aura Biosciences, Inc. (AURA) reported EPS (basic) of -$0.50 in Q1 2026.
How has Aura Biosciences, Inc.'s EPS (basic) changed year-over-year?
Aura Biosciences, Inc.'s EPS (basic) increased by 9.1% year-over-year, from -$0.55 to -$0.50.
What is the long-term trend for Aura Biosciences, Inc.'s EPS (basic)?
Over 3 years (2022 to 2025), Aura Biosciences, Inc.'s EPS (basic) has grown at a -3.0% compound annual growth rate (CAGR), from -$1.96 to -$1.79.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.